Telomir Pharmaceuticals Files 8-K
Ticker: TELO · Form: 8-K · Filed: Jun 2, 2025 · CIK: 1971532
Sentiment: neutral
Topics: 8-K, disclosure
TL;DR
Telomir Pharma filed an 8-K for 'Other Events' - details TBD.
AI Summary
On June 2, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific details regarding the nature of these events, any associated financial figures, or involved parties were provided in the excerpt.
Why It Matters
This filing signals a material event has occurred for Telomir Pharmaceuticals, requiring disclosure to investors. However, the lack of detail in the provided excerpt leaves the specific impact and nature of the event unknown.
Risk Assessment
Risk Level: medium — The filing of an 8-K for 'Other Events' suggests a potentially significant development, but the absence of specific information creates uncertainty and potential risk for investors.
Key Players & Entities
- Telomir Pharmaceuticals, Inc. (company) — Registrant
- June 2, 2025 (date) — Date of earliest event reported
FAQ
What specific event(s) are being reported under "Other Events" in this 8-K filing?
The provided excerpt does not specify the nature of the "Other Events" being reported by Telomir Pharmaceuticals, Inc.
Are there any financial implications associated with the "Other Events" disclosed in the filing?
The excerpt does not mention any specific dollar amounts or financial figures related to the "Other Events".
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on June 2, 2025.
What is the principal executive office address for Telomir Pharmaceuticals, Inc.?
The principal executive offices are located at 100 SE 2nd St, Suite 2000, #1009, Miami, Florida.
What is the IRS Employer Identification Number for Telomir Pharmaceuticals, Inc.?
The IRS Employer Identification Number for Telomir Pharmaceuticals, Inc. is 87-2606031.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 2, 2025 regarding Telomir Pharmaceuticals, Inc. (TELO).